Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of THB335 in Adult Participants With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Standard-of-Care Treatment

NCT07766499 is registered in ClinicalTrials.gov with Calixis Inc. as lead sponsor.

NCT NCT07766499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07766499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of THB335 in Adult Participants With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Standard-of-Care Treatment
Lead sponsor
Calixis Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
January 31, 2028
Enrollment
81 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic idiopathic urticaria, chronic spontaneous urticaria (csu)